Yes. That’s true about the cost. Having liv
Post# of 153886
(Total Views: 932)
Posted On: 09/27/2020 4:57:19 AM
Re: LA goelette #58089
Yes. That’s true about the cost. Having lived in Mexico for 30 yrs and having done volunteer work for most of that time right up till the pandemic, I certainly understand that certain drugs such as LL are out of the reach of most people. The hope was govt. or some billionaire’s foundation would make the drug accessible. I used to post about accessibility a few months ago, but fortunately, at least here in Mexico, there are many alternative treatments plus mandatory vaccines that were thought to help. Mexico didn’t really fully close down because people didn’t have that luxury and according to the charts we are not doing that bad compared to other countries. Not great, but not that bad, considering social distancing has been a challenge.
I think the importance of COVID approval has a lot more to do with the validation of LL. The approval will help with other indications such as cancer where the SOC cost of treatment would justify the use of LL across the board in any country especially taking into account the safety profile. In any event, at this point in time it would be counterproductive to not go forward with the COVID trials. The long haulers study is a key opportunity to study how LL crosses the BBB and it’s effect on cognition and inflammation in the brain. Longhaulers is a gift! There is already a waiting list. Try enrolling a brain trial under normal conditions! (It’s hard to imagine people wanting to sign up for a clinical trial, not just ours - any trial, and be a human guinea pig. )
That being said, COVID whose enrollment has been relatively fast has given us the opportunity to better understand how LL works and how inflammatory diseases affect our health. Literally, COVID has saved us time and should help CYDY design better trials in the future.
Business is business and I thought the comment about test kits very interesting. The first question that popped into my mind was how much Incelldx was going to sell them for. I know when I go to a lab for tests, the diagnostics are often costlier than the actual treatment. In other words, regardless of the treatment, BP will make buckaroos. We all know by now he is an astute businessman. In some interview he said something about being a scientist vs a businessman and always being able to tell the difference. Unfortunately, the guys at CYDY aren’t. As long as they make sure to protect their IP, blunders should only be temporary. The day they use it as collateral, who knows what the note holders will do to get their hands on it?
Thanks for your comments. I too try to balance the good and the bad and enjoy reading everyone’s point of view/info. It sure beats those “to da moon!/stupid short!” posts which are beyond tiresome.
I think the importance of COVID approval has a lot more to do with the validation of LL. The approval will help with other indications such as cancer where the SOC cost of treatment would justify the use of LL across the board in any country especially taking into account the safety profile. In any event, at this point in time it would be counterproductive to not go forward with the COVID trials. The long haulers study is a key opportunity to study how LL crosses the BBB and it’s effect on cognition and inflammation in the brain. Longhaulers is a gift! There is already a waiting list. Try enrolling a brain trial under normal conditions! (It’s hard to imagine people wanting to sign up for a clinical trial, not just ours - any trial, and be a human guinea pig. )
That being said, COVID whose enrollment has been relatively fast has given us the opportunity to better understand how LL works and how inflammatory diseases affect our health. Literally, COVID has saved us time and should help CYDY design better trials in the future.
Business is business and I thought the comment about test kits very interesting. The first question that popped into my mind was how much Incelldx was going to sell them for. I know when I go to a lab for tests, the diagnostics are often costlier than the actual treatment. In other words, regardless of the treatment, BP will make buckaroos. We all know by now he is an astute businessman. In some interview he said something about being a scientist vs a businessman and always being able to tell the difference. Unfortunately, the guys at CYDY aren’t. As long as they make sure to protect their IP, blunders should only be temporary. The day they use it as collateral, who knows what the note holders will do to get their hands on it?
Thanks for your comments. I too try to balance the good and the bad and enjoy reading everyone’s point of view/info. It sure beats those “to da moon!/stupid short!” posts which are beyond tiresome.
(17)
(0)